SBIR/STTR Research Award
Facilitating supervised self-management of stimulant medications among adolescents: improving adherence, reducing stigma, and supporting caregivers
Award amount
$379,072Program and phase
SBIR · Phase IAward year
2021Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- PillSmart Inc.
- Proposal award date
- 2021-06-01
- Contract end date
- 2022-05-31
- UEI
- TQCCBVNKHRK4
- Solicitation number
- PAR22-073
- Topic code
- NIDA
Research abstract
PillSmart: AbstractStimulant medications are efficacious in reducing impulsivity and other ADHD symptoms in youth,
which is important because youth with ADHD have an increased risk of developing substance use disorders.
Youth's non-adherence of stimulant medications is prevalent (~47-60%), and the misuse of prescribed stimu-
lants is increasing among youth (~5-34%), which poses a serious public health concern. Without adequate
monitoring support by parental caregivers, stimulant misuse and non-adherence in youth can increase the risk
of substance use disorders, overdose, psychosis, and suicidality. There are no available evidence-based tools
or interventions demonstrated to improve stimulant adherence and reduce misuse among youth with ADHD.Most adherence aids (e.g., medication reminder apps, 7-day pill organizers, smart pill caps) fail to ad-
dress the potential misuse of stimulants as they cannot regulate medication access. Pill dispensers are effec-
tive at improving medication safety and adherence, but they are designed for older adult/elderly patients, and
they are not ideal for youth due to their large and heavy size. Our pilot data suggest that youth are concerned
about stigma from others when using their medication, and the use of current dispensers could hinder adher-
ence by potentially soliciting unwanted attention and triggering anticipated stigma (i.e., worry/concern about
negative reactions from others).PillSmart™ is a primary prevention intervention that uses a novel, sleek, and discreet pill dispensing
device (prototype developed) and mobile app (prototype). PillSmart's pocket-sized pill dispenser aims to pre-
vent misuse by securely storing medication and only dispensing the programmed dose at the scheduled time.
PillSmart's interoperating mobile app aims to improve adherence and mitigate the parental burden by facilitat-
ing remote supervision of the stimulant medication regimen. The overarching goal of this project is to develop
PillSmart's system as an evidence-based prevention intervention to improve adolescents' health outcomes as
they mature into adulthood, reduce caregiver burden, and increase medication adherence and safety.The aims of our SBIR Phase I project are to fully develop a portable, affordable medication manage-
ment system, test its usability, and assess its feasibility to facilitate self-management of stimulant medications
among adolescents with ADHD, improve medication adherence, and reduce parental caregiver burden. Upon
the completion of the milestones in Phase 1, we will be prepared to transition into Phase II of the research
where we plan to conduct a multisite randomized clinical trial and to integrate evidence-based behavioral ap-
proaches. We anticipate the technology's benefits to apply for adolescents with ADHD and also adolescents
with other chronic health conditions (e.g., depression, anxiety, Type-2 diabetes).
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)